Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 2CNS 2Breast 2Thoracic 1NET 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Vipoma 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Gastrinoma 1Carcinoma 1Carcinoid Tumor 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × epothilone B × Endocrine × Clear all
NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Novartis

Phase 2 Completed
33 enrolled
EndocrineNET

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡